Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 4:28 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 289 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vascular Testing Clear all
Completed Not applicable Interventional

Implementation of ABI and WIfI in Rural Health Clinics

NCT04337723
View directory record Official record
Conditions
Peripheral Arterial Disease, Diabetic Foot, Diabetes Mellitus
Interventions
ABI/WIFI scoring
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting Phase 3 Interventional

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

NCT07198074
View directory record Official record
Conditions
Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma
Interventions
Bevacizumab, Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Paclitaxel, Pembrolizumab
Biological · Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
303
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 226 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting Not applicable Interventional

Hemodynamics After Resistance Training

NCT07022340
View directory record Official record
Conditions
Perimenopause
Interventions
Resistance Training Intervention
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
40 Years to 60 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Phase 1 Interventional

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

NCT05249426
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
BI 765063, Ezabenlimab, BI 836880, Cetuximab, Investigator´s Choice Chemotherapy
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Completed No phase listed Observational

Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center

NCT01465360
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia, Primary Progressive Aphasia, Parkinson' Disease Dementia, Mixed Dementia
Interventions
Not listed
Lead sponsor
Exonhit
Industry
Eligibility
21 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
3
States / cities
Las Vegas, Nevada • Cleveland, Ohio • Lakewood, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 6, 2012 · Synced Oct 18, 2026, 4:28 AM EDT
Terminated Phase 2 Interventional

CXA-10 Study in Subjects With Pulmonary Arterial Hypertension

NCT04053543
View directory record Official record
Conditions
PAH
Interventions
CXA-10
Drug
Lead sponsor
Complexa, Inc.
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 27 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2020 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Branched-Chain Amino Acid Metabolism on Limb Dysfunction in PAD

NCT03490968
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Supervised Exercise, Vascular Assessment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
50 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Characterization of the Cardiac Phenotype of Friedreich's Ataxia (FRDA)

NCT02316314
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Cardiac magnetic resonance imaging (CMR), Exercise-stress test, Echocardiogram (ECHO), Cardiac-related blood studies
Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 50 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Phase 2 Interventional Results available

Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH

NCT02734953
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nitric Oxide
Drug
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

NCT03239145
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Pembrolizumab, Trebananib
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Longitudinal Cognitive Assessment by BoCA

NCT04114994
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia, Frontotemporal Dementia, Parkinson Disease, Multiple Sclerosis, TBI
Interventions
Boston Cognitive Assessment (BoCA)
Diagnostic Test
Lead sponsor
Alzheimer's Light LLC
Industry
Eligibility
50 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Racial and Aging Effects of Acute Antioxidant Supplementation

NCT02157207
View directory record Official record
Conditions
Healthy
Interventions
Antioxidant, Placebo
Dietary Supplement · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
93 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 16, 2015 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Discharge Educational Strategies for Reduction of Vascular Events

NCT01836354
View directory record Official record
Conditions
Intracerebral Infarcts, Ischemic Stroke, Hemorrhagic Strokes, TIA's
Interventions
DESERVE education
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
3
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 18, 2026, 4:28 AM EDT
Completed No phase listed Observational

Brain Markers Predicting Reading Recovery After Stroke

NCT03845686
View directory record Official record
Conditions
Left-Hemisphere Stroke
Interventions
Perfusion functional Magnetic Resonance Imaging (perfusion fMRI)
Diagnostic Test
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Oct 18, 2026, 4:28 AM EDT
Active, not recruiting Not applicable Interventional

The Chocolate Touch Study

NCT02924857
View directory record Official record
Conditions
Peripheral Artery Disease (PAD), Ischemia, Intermittent Claudication
Interventions
Chocolate Touch, Lutonix Drug Coated Balloon
Device
Lead sponsor
TriReme Medical, LLC
Industry
Eligibility
18 Years and older
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
15
States / cities
Gainesville, Florida • Miami Beach, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2023 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Effects of LycoRed Phytonutrient and Vitamin Supplement (a.k.a. LYC-001e) on Ocular Blood Flow

NCT03068377
View directory record Official record
Conditions
Ocular Blood Flow
Interventions
Experimental, Placebo
Dietary Supplement
Lead sponsor
LycoRed Ltd.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Recruiting Phase 3 Interventional

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT05863195
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm in the Liver, Stage IV Colorectal Cancer AJCC v8, Unresectable Colorectal Carcinoma
Interventions
Bevacizumab, Capecitabine, Cetuximab, Computed Tomography, Floxuridine, Fluorouracil, Implantation, Intrahepatic Infusion Procedure, Irinotecan, Leucovorin, Magnetic Resonance Imaging, Oxaliplatin, Panitumumab, Single Photon Emission Computed Tomography
Biological · Drug · Procedure
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
62
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 48 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Not listed No phase listed Observational

Keller Prehospital Ultrasound Study

NCT01074112
View directory record Official record
Conditions
Ultrasonography, Multiple Trauma, Kidney Calculi, Aortic Aneurysm, Abdominal, Pregnancy, Catheterization, Venous
Interventions
EFAST exam, Pelvic Ultrasound, Ultrasound Guided Vascular Access, Focused Ultrasound Scan, Cardiac Ultrasound
Device · Procedure
Lead sponsor
Keller Fire Rescue
Government
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Keller, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2010 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Phase 3 Interventional Results available

A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery

NCT05425056
View directory record Official record
Conditions
Complication of Renal Dialysis, End Stage Renal Disease, End Stage Kidney Disease, ESRD, Chronic Kidney Failure, Complication of Hemodialysis, Vascular Access Complication, Arteriovenous Fistula
Interventions
Sirolimus
Drug
Lead sponsor
Vascular Therapies, Inc.
Industry
Eligibility
65 Years and older
Enrollment
136 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
17
States / cities
San Diego, California • Torrance, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Does Blood Vessel Vasodilation, Caused by Focal Infiltration of Lidocaine Cause Temporary Nerve Functional Recovery for Patients with Common Peroneal Nerve Injury or Entrapment: Testing the 'Phoenix Sign' Effect Between Lidocaine (a Common Local Anesthetic) and Papaverine, a Know Vasodilator

NCT06637046
View directory record Official record
Conditions
Drop Foot
Interventions
Diagnostic procedures, Lidocaine HCl
Diagnostic Test
Lead sponsor
Stephen Barrett
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Marietta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 18, 2026, 4:28 AM EDT
Completed Not applicable Interventional

Improving Age-Related Cognitive Decline With Exercise in Hypertensive Older Adults

NCT05043454
View directory record Official record
Conditions
Hypertension
Interventions
High Intensity Interval Training (HIIT) Exercise
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
55 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 18, 2026, 4:28 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.

NCT00938665
View directory record Official record
Conditions
Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment, Frontotemporal Dementia
Interventions
COGNISION™ System
Device
Lead sponsor
Neuronetrix, Inc.
Industry
Eligibility
60 Years to 90 Years
Enrollment
204 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
7
States / cities
West Palm Beach, Florida • Lexington, Kentucky • Louisville, Kentucky + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 18, 2026, 4:28 AM EDT